Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Cited by 279 Publications

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Science, 2019, 363(6429)

PubMed: 30792274 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):46-63

PubMed: 30581152 ( click the link to review the publication )

Nature, 2018, 560(7718):325-330

PubMed: 30089904 ( click the link to review the publication )

Nature, 2017, 550(7677):534-538

PubMed: 29045385 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell, 2017, 171(5):1094-1109

PubMed: 29149604 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):748-760

PubMed: 29232553 ( click the link to review the publication )

Nat Med, 2014, 20(6):599-606

PubMed: 24813251 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):242-52

PubMed: 22862949 ( click the link to review the publication )

Nat Commun, 2019, 10(1):273

PubMed: 30655516 ( click the link to review the publication )

Leukemia, 2019, 33(1):171-180

PubMed: 30026574 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31138526 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):28

PubMed: 30717817 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31142515 ( click the link to review the publication )

Cell Rep, 2019, 27(6):1657-1665

PubMed: 31067453 ( click the link to review the publication )

J Control Release, 2019, 306:149-164

PubMed: 31121280 ( click the link to review the publication )

Cancer Lett, 2019, 442:233-241

PubMed: 30419344 ( click the link to review the publication )

PLoS Pathog, 2019, 15(1):e1007498

PubMed: 30645648 ( click the link to review the publication )
Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.006

PubMed: 31303577 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(7):1205-1216

PubMed: 31092565 ( click the link to review the publication )

Hum Mutat, 2019, 40(4):392-403

PubMed: 30609140 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(3):1653-1664

PubMed: 29916141 ( click the link to review the publication )

Neoplasia, 2019, 21(7):653-664

PubMed: 31132676 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:1659468

PubMed: 31281566 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(2):252-263

PubMed: 30445147 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30736330 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

Food Chem Toxicol, 2019, 131:110537

PubMed: 31150782 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Gene, 2019, 707:86-92

PubMed: 31071385 ( click the link to review the publication )

Cell Signal, 2019, 62:109351

PubMed: 31260799 ( click the link to review the publication )

Biochimie, 2019, 162:46-54

PubMed: 30946948 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1140-1146

PubMed: 31103265 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1616190

PubMed: 31111763 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2019, 392(4):461-466

PubMed: 30554340 ( click the link to review the publication )

J Blood Med, 2019, 10:105-109

PubMed: 31043801 ( click the link to review the publication )
Biochim Biophys Acta Gen Subj, 2019, 1863(6):1108-1115

PubMed: 30974160 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2877-2893

PubMed: 29863498 ( click the link to review the publication )

Leukemia, 2018, 32(1):139-148

PubMed: 28663576 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Blood Cancer J, 2018, 8(11):105

PubMed: 30409995 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):29

PubMed: 29482577 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1416-1429

PubMed: 29703842 ( click the link to review the publication )

Lab Invest, 2018, 98(6):708-714

PubMed: 29540860 ( click the link to review the publication )

Exp Cell Res, 2018, 369(1):120-128

PubMed: 29772221 ( click the link to review the publication )

Int Immunopharmacol, 2018, 54:39-45

PubMed: 29100036 ( click the link to review the publication )

Mol Cells, 2018, 41(12):1008-1015

PubMed: 30396235 ( click the link to review the publication )

Eur J Pharmacol, 2018, 830:17-25

PubMed: 29680228 ( click the link to review the publication )

Oncol Res, 2018, 26(3):421-429

PubMed: 28899456 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 501(1):286-292

PubMed: 29729272 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 505(1):126-133

PubMed: 30236985 ( click the link to review the publication )

J Bone Miner Metab, 2018, 36(5):537-546

PubMed: 29027021 ( click the link to review the publication )

Ann Diagn Pathol, 2018, 32:28-34

PubMed: 29414394 ( click the link to review the publication )

Viruses, 2018, 10(10)

PubMed: 30261679 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1692

PubMed: 29167449 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):1012-1024

PubMed: 28151717 ( click the link to review the publication )

Leukemia, 2017, 31(7):1570-1581

PubMed: 27890927 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(10):839-846

PubMed: 28903971 ( click the link to review the publication )

Cancer Res, 2017, 77(22):6282-6298

PubMed: 28978635 ( click the link to review the publication )
Cancer Res, 2017, 77(11):2927-2937

PubMed: 28404587 ( click the link to review the publication )

Genomics Inform, 2017, 15(3):87-97

PubMed: 29020724 ( click the link to review the publication )

Cancer Lett, 2017, 405:63-72

PubMed: 28716527 ( click the link to review the publication )

Exp Mol Med, 2017, 49(8):e365

PubMed: 28798402 ( click the link to review the publication )

J Cancer, 2017, 8(5):839-851

PubMed: 28382147 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3097-3108

PubMed: 28938421 ( click the link to review the publication )

Biomed Pharmacother, 2017, 88:562-568

PubMed: 28131096 ( click the link to review the publication )

BMC Genomics, 2017, 18(1):127

PubMed: 28166733 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Mol Brain, 2017, 10(1):7

PubMed: 28196470 ( click the link to review the publication )

Life Sci, 2017, 173:36-42

PubMed: 28212825 ( click the link to review the publication )

Neurotox Res, 2017, 32(4):555-562

PubMed: 28612296 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(2):400-406

PubMed: 28502636 ( click the link to review the publication )

Oncol Lett, 2017, 13(2):647-654

PubMed: 28356941 ( click the link to review the publication )

Cancer Metab, 2017, 5:7

PubMed: 28855983 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Cell, 2017, 170(5):860-874

PubMed: 28803730 ( click the link to review the publication )

Cell, 2017, 169(6):1105-1118

PubMed: 28575672 ( click the link to review the publication )

Sci Rep, 2017, 7(1):682

PubMed: 28386133 ( click the link to review the publication )

Sci Transl Med, 2016, 8(339):339ra70

PubMed: 27194728 ( click the link to review the publication )

Hepatology, 2016, 64(1):161-74

PubMed: 26926206 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Leukemia, 2016, 30(4):861-72

PubMed: 26658839 ( click the link to review the publication )
Cancer Res, 2016, 76(12):3531-40

PubMed: 27197154 ( click the link to review the publication )

Blood Cancer J, 2016, 6(7):e446

PubMed: 27421095 ( click the link to review the publication )

Cancer Lett, 2016, 372(1):82-8

PubMed: 26721204 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Lab Chip, 2016, 16(2):334-44

PubMed: 26660268 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(8):1075-81

PubMed: 27087021 ( click the link to review the publication )

Am J Pathol, 2016, 186(3):678-90

PubMed: 26801735 ( click the link to review the publication )

J Biol Chem, 2016, 291(2):939-47

PubMed: 26527686 ( click the link to review the publication )

Int J Oncol, 2016, 49(5):1848-1858

PubMed: 27601063 ( click the link to review the publication )

Eur J Cell Biol, 2016, 95(10):389-400

PubMed: 27567537 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0168193

PubMed: 27978543 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150484

PubMed: 26930278 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(7):1677-86

PubMed: 26421357 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(6):783-798

PubMed: 27250763 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):751-60

PubMed: 27045812 ( click the link to review the publication )

Sarcoma, 2016, 2016:3484673

PubMed: 27822137 ( click the link to review the publication )

Drug Discov Ther, 2016, 10(4):195-200

PubMed: 27594296 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71790-71801

PubMed: 27708243 ( click the link to review the publication )

Mol Cells, 2016, 39(12):898-908

PubMed: 28008160 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1462

PubMed: 25748087 ( click the link to review the publication )

Leukemia, 2015, 29(6):1390-401

PubMed: 25533804 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2109

PubMed: 25712341 ( click the link to review the publication )
Biomaterials, 2015, 73:70-84

PubMed: 26402156 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 211:44-52

PubMed: 26031842 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.455

PubMed: 25619841 ( click the link to review the publication )

Oncogene, 2015, 34(16):2138-2144

PubMed: 24909167 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-50

PubMed: 25973303 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Traffic, 2015, 10.1111/tra.12287

PubMed: 25824657 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: ( click the link to review the publication )

Toxicol Sci, 2015, 10.1093/toxsci/kfv056

PubMed: 25766884 ( click the link to review the publication )

Sci Rep, 2015, 5:13001

PubMed: 26306624 ( click the link to review the publication )

J Biol Chem, 2015, 290(50):29854-68

PubMed: 26483548 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-650

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 283(1):1-8

PubMed: 25576094 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25817892 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: 25422130 ( click the link to review the publication )

Phys Chem Chem Phys, 2015, 17(29):18971-9

PubMed: 26126833 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15:444

PubMed: 26025442 ( click the link to review the publication )

Biomed Rep, 2015, 3(6):797-801

PubMed: 26623018 ( click the link to review the publication )

Malar J, 2015, 14(1):200

PubMed: 25968882 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )
J Bio Mater Res, 2015, 103(4):1476-84

PubMed: ( click the link to review the publication )

Chem Biol, 2015, 10.1016/j.chembiol.2015.01.004

PubMed: 25728267 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Sci Transl Med, 2014, 6(250):250ra112

PubMed: 25143362 ( click the link to review the publication )

Blood, 2014, 123(26):4120-31

PubMed: 24711662 ( click the link to review the publication )

J Clin Invest, 2014, 124(9):3757-66

PubMed: 25061876 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1576-89

PubMed: 24634471 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(16):E1591-9

PubMed: 24715725 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2803-15

PubMed: 24686171 ( click the link to review the publication )

Cancer Res, 2014, 74(11):3127-36

PubMed: 24755468 ( click the link to review the publication )

J Cell Biol, 2014, 205(6):771-80

PubMed: 24934156 ( click the link to review the publication )

Cell Death Differ, 2014, 21(12):1838-51

PubMed: 25034784 ( click the link to review the publication )

Mol Cancer, 2014, 13(1):159

PubMed: 24972933 ( click the link to review the publication )

Int J Cancer, 2014, 135(12):2950-61

PubMed: 24771510 ( click the link to review the publication )

Eur J Cancer, 2014, 51(1):1-8

PubMed: 25466507 ( click the link to review the publication )

Cancer Lett, 2014, 343(2):286-94

PubMed: 24120758 ( click the link to review the publication )

Br J Cancer, 2014, 110(9):2224-31

PubMed: 24691427 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1126

PubMed: 24625985 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1580

PubMed: 25522274 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )
J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Am Heart Assoc, 2014, 3(1):e000520

PubMed: 24572252 ( click the link to review the publication )

J Nutr Biochem, 2014, 25(5):515-25

PubMed: 24613086 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt13):2898-909

PubMed: 24806960 ( click the link to review the publication )

J Virol, 2014, 87(23):13035-41

PubMed: 24027330 ( click the link to review the publication )

Eur J Immunol, 2014, 44(6):1604-14

PubMed: 24643698 ( click the link to review the publication )

J Leukocyte Biol, 2014, 95(3):461-9

PubMed: 24231258 ( click the link to review the publication )

Cancer Gene Ther, 2014, 21(11):472-82

PubMed: 25323693 ( click the link to review the publication )

J Biol Chem, 2014, 289(17):11906-15

PubMed: 24570003 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14075-88

PubMed: 24711452 ( click the link to review the publication )

J Proteome Res, 2014, 13(5):2223-38

PubMed: 24669782 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(19):3570-8

PubMed: 25022755 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(9):C774-87

PubMed: 25143351 ( click the link to review the publication )

World J Gastroenterol, 2014, 20(48):18207-15

PubMed: 25561788 ( click the link to review the publication )

J Biomed Mater Res A, 2014, 10.1002/jbm.a.35286

PubMed: 25046528 ( click the link to review the publication )

Hematol Oncol, 2014, 10.1002/hon.2179

PubMed: 25394177 ( click the link to review the publication )

Neurotoxicology, 2014, 42:33-48

PubMed: 24705302 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 73(1):69-77

PubMed: 24190701 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 10.1007/s00280-014-2451-7

PubMed: 24842158 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(6):e99211

PubMed: 24911872 ( click the link to review the publication )

PLoS One, 2014, 9(3):e89848

PubMed: 24595136 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107009

PubMed: 25255316 ( click the link to review the publication )
Mol Cell Biochem, 2014, 398(1-2):165-73

PubMed: 25292312 ( click the link to review the publication )

J Nanopart Res, 2014, 42:33-48

PubMed: http://link.springer.com/article/10.1007/s11051-01 ( click the link to review the publication )

Biosciences biotechnology research asia, 2014, 10.13005bbra.1309

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:5896

PubMed: 25077633 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Hepatology, 2013, 57(2):625-36

PubMed: 22991197 ( click the link to review the publication )

Nat Chem Biol, 2013, 10(1):61-8

PubMed: 24292069 ( click the link to review the publication )

Nat Protoc, 2013, 8(6):1155-68

PubMed: 23702832 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5591-601

PubMed: 24004671 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(9):3501-6

PubMed: 23382202 ( click the link to review the publication )

Cancer Res, 2013, 74(1):56-67

PubMed: 24310398 ( click the link to review the publication )

Mucosal Immunol, 2013, 7(4):857-68

PubMed: 24280938 ( click the link to review the publication )

Int J Cancer, 2013, 133(6):1357-67

PubMed: 23463417 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(6):R107

PubMed: 24207099 ( click the link to review the publication )

Br J Dermatol, 2013, 168(3):504-12

PubMed: 23445313 ( click the link to review the publication )

Free Rad Biol Med, 2013, 65:778-88

PubMed: 23973637 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e50

PubMed: 24158003 ( click the link to review the publication )

Pain, 2013, 154(11):2432-40

PubMed: 23891899 ( click the link to review the publication )

Expert Opin Drug Deliv, 2013, 10(10):1345-52

PubMed: 23937147 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1012-8

PubMed: 23916134 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(3):578-87

PubMed: 23198928 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(2):383-90

PubMed: 23107612 ( click the link to review the publication )

J Virol, 2013, 87(21):11872-83

PubMed: 23986594 ( click the link to review the publication )
Biochim Biophys Acta, 2013, 1830(10):4456-69

PubMed: 23742826 ( click the link to review the publication )

Biochem Pharmacol, 2013, 85(11):1611-8

PubMed: 23523860 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

J Trauma Acute Care Surg, 2013, 74(2):499-507

PubMed: 23354244 ( click the link to review the publication )

Mol Biol Cell, 2013, 35:215-22

PubMed: 24145151 ( click the link to review the publication )

Clin Exp Metastasis, 2013, 30(4):407-15

PubMed: 23412907 ( click the link to review the publication )

Retrovirology, 2013, 10(1):120

PubMed: 24156270 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1551-62

PubMed: 23877657 ( click the link to review the publication )

Toxicol Lett, 2013, 223(2):109-15

PubMed: 24055520 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(6):1335-42

PubMed: 24121478 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59390

PubMed: 23527180 ( click the link to review the publication )

PLoS One, 2013, 8(9):e75280

PubMed: 24086494 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82053

PubMed: 24312627 ( click the link to review the publication )

Eur J Haematol, 2013, 91(4):339-46

PubMed: 23869695 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1302-8

PubMed: 23896061 ( click the link to review the publication )

J Int Med Res, 2013, 41(5):1505-19

PubMed: 23975859 ( click the link to review the publication )

Curr Protoc Chem Biol, 2013, 5(3):195-212

PubMed: 24391083 ( click the link to review the publication )

Blood, 2012, 119(24):5772-81

PubMed: 22538852 ( click the link to review the publication )

Blood, 2012, 119(11):2579-89

PubMed: 22262760 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4669-81

PubMed: 22806876 ( click the link to review the publication )

Br J Pharmacol, 2012, 168(8):1868-77

PubMed: 23194305 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(5):1487-96

PubMed: 22377766 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e295

PubMed: 22495350 ( click the link to review the publication )
FASEB J, 2012, 26(5):1855-65

PubMed: 22345405 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(11):2321-30

PubMed: 22964485 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(10):2243-53

PubMed: 22933706 ( click the link to review the publication )

Br J Haematol, 2012, 157(6):718-31

PubMed: 22533681 ( click the link to review the publication )

J Virol, 2012, 86(18):10112-22

PubMed: 22787216 ( click the link to review the publication )

J Virol, 2012, 86(24):13360-70

PubMed: 23015717 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2012, 303(3):E410-21

PubMed: 22669242 ( click the link to review the publication )

J Biol Chem, 2012, 287(13):10344-54

PubMed: 22318734 ( click the link to review the publication )

J Biol Chem, 2012, 288(2):1125-34

PubMed: 23209294 ( click the link to review the publication )

J Biol Chem, 2012, 288(4):2721-33

PubMed: 23209292 ( click the link to review the publication )

J Biol Chem, 2012, 287(41):34722-9

PubMed: 22910913 ( click the link to review the publication )

J Pharmacol Exp Ther, 2012, 343(1):184-97

PubMed: 22787116 ( click the link to review the publication )

Prostate, 2012, 72(10):1140-9

PubMed: 22127954 ( click the link to review the publication )

Cell Cycle, 2012, 11(9):1804-17

PubMed: 22510564 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Biol Reprod, 2012, 87(2):44

PubMed: 22592496 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29541

PubMed: 22235305 ( click the link to review the publication )

PLoS One, 2012, 7(4):e34684

PubMed: 22514654 ( click the link to review the publication )

Exp Mol Pathol, 2012, 93(1):99-110

PubMed: 22475623 ( click the link to review the publication )

Steroids, 2012, 77(11):1025-32

PubMed: 22683670 ( click the link to review the publication )

J Biomol Screen, 2012, 17(9):1231-42

PubMed: 22927676 ( click the link to review the publication )

J Biomol Screen, 2012, 17(5):572-80

PubMed: 22357874 ( click the link to review the publication )

Biochem Cell Biol, 2012, 90(2):224-31

PubMed: 22397456 ( click the link to review the publication )

Saint Louis University, 2012, 2012/0270829

PubMed: ( click the link to review the publication )
Sarcoma, 2012, 2012:805614

PubMed: 22919280 ( click the link to review the publication )

Blood, 2011, 118(14):3922-31

PubMed: 21841164 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Development, 2011, 138(14):2903-8

PubMed: 21653611 ( click the link to review the publication )

Br J Haematol, 2011, 155(5):588-98

PubMed: 21950728 ( click the link to review the publication )

J Biol Chem, 2011, 286(18):16018-29

PubMed: 21454483 ( click the link to review the publication )

Exp Cell Res, 2011, 317(18):2671-82

PubMed: 21871886 ( click the link to review the publication )

Int Immunopharmacol, 2011, 11(12):2242-5

PubMed: 21979495 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23712

PubMed: 21887304 ( click the link to review the publication )

Cell Biochem Biophys, 2011, 60(3):173-85

PubMed: 21132543 ( click the link to review the publication )

University of Porto, 2011, Mireia Vila Gasull

PubMed: ( click the link to review the publication )

Glia, 2010, 58(16):1961-76

PubMed: 20830808 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

J Virol, 2010, 84(18):9439-51

PubMed: 20592098 ( click the link to review the publication )

J Biol Chem, 2010, 285(52):41074-86

PubMed: 20956535 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Targets

20S proteasome ^[1]
(Cell-free assay)

0.6 nM(Ki)

In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. ^[2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF-7	MoD2R5l1d3SxeHnjJGF{e2G7	MYW1NEDPxE1?	NF;RdGM1QCCq	NFG5SXhFVVOR	M122ZmtqdGy\|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU>	NF:5UG8yODR7OU[0Ny=>
OVCA 429	NXHvPZlvTnWwY4Tpc44hSXO\|YYm=	NHT3fm0{ODBibl2=	M1PFe\|Q5KGh?	M3LaV2ROW09?	NEXDZoRFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM>	NYrIU4lIOTB7OUm3OlY>
RPMI8226	NHfUR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInKWnAyODBibl2=	NFHnNYs1QCCq	M3P1RmROW09?	MmrkTWM2OD1\|MDDuUS=>	M1jIVlEyOzB4NEi5
Dox40	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUW4NY9JOTByIH7N	NFzXPYw1QCCq	M3rsS2ROW09?	NWDJZ3A6UUN3ME20NEBvVQ>?	M{fWTlEyOzB4NEi5
MR20	NFTTc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D1NFExOCCwTR?=	NIOzenE1QCCq	NXjqd25wTE2VTx?=	NGfxOIpKSzVyPUKwJI5O	MmHCNVE{ODZ2OEm=
LR5	NVGyWYxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnK[oYyODBibl2=	NGLCRXE1QCCq	MmXRSG1UVw>?	MU\JR\|UxRTJyIH7N	NWfBN3o3OTF\|ME[0PFk>
U266	Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVqxNFAhdk1?	MYC0PEBp	NEDoboxFVVOR	MYLJR\|UxRTNibl2=	M1LGdlEyOzB4NEi5
IM-9	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLmZ2YyODBibl2=	NGPK[Vk1QCCq	MV3EUXNQ	NV3QUpJ5UUN3ME22JI5O	NWK1ZWlyOTF\|ME[0PFk>
Hs Sultan	NIrWe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7GUJMyODBibl2=	NYPxd2I4PDhiaB?=	MXvEUXNQ	M4H5PGlEPTB;MkCgcm0>	NFz2bJcyOTNyNkS4PS=>
PAM-LY2	MlPZSpVv[3Srb36gRZN{[Xl?	NEThZocyODBibl2=	M1W5SVEzKGh?	MXrEUXNQ	Ml[xTY5pcWKrdIOgUmYu\|rqEIHHjeIl3[XSrb36=	NEm1TGUyOTN3MEmxNy=>
PAM 212	M13Vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;sb\|J2OTByIH7N	NV\ncZd5PzJiaB?=	MXjEUXNQ	MmPQTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	MXuxNVM2ODlzMx?=
PAM-LY2	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSxNFAhdk1?	NHnxZXE4OiCq	MoXjSG1UVw>?	MmPOTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	MWexNVM2ODlzMx?=
B4B8	MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnGWIQyODBibl2=	M{SzdVczKGh?	NUDaWldOTE2VTx?=	MYnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	NFXhWZoyOTN3MEmxNy=>
B7E3	NIrhcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{T1SVExOCCwTR?=	MV23NkBp	M3HoWGROW09?	M{THTmlvcGmkaYTzJINmdGxidnnhZoltcXS7	MYGxNVM2ODlzMx?=
UM-SCC-9	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\DbIcyODBibl2=	MnjIO\|IhcA>?	M3;YUWROW09?	M4LQZWlvcGmkaYTzJINmdGxidnnhZoltcXS7	NGjteWUyOTN3MEmxNy=>
UM-SCC-11B	M1\HPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvZNVAxKG6P	NXyxdINsPzJiaB?=	M{m2fmROW09?	NH3ZWlFKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	NWmzVYpIOTF\|NUC5NVM>
H460	M3rtPGZ2dmO2aX;uJGF{e2G7	MYexNEDPxE1?	Mkj0NlQhcA>?	MYXEUXNQ	MmDITY5lfWOnczDCZ4wuOiCyaH;zdIhwenmuYYTpc44h[W6mIHPs[YF3[WenIHPvdpJmdGG2ZXSge4l1cCCJMj3NJJBp[XOnIHHydoV{fA>?	MoHWNVI1QTJzMUe=
U266	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnFOVAxKG6pL33s	MkXsOFghcA>?	M1TDVGROW09?	NIe3[5BKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	M3XtVlEzPjNzNkG5
ARH77	NYCwRWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nLe\|UxOCCwZz;tcC=>	NVm2[WlkPDhiaB?=	MVzEUXNQ	NITHdWhKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	NVra[XZKOTJ4M{G2NVk>
WAD-1	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXkSY9HPTByIH7nM41t	MnnMOFghcA>?	MWnEUXNQ	NY\FTJVlUW6qaXLpeJMh[2WubDDndo94fGh?	M3zpNVEzPjNzNkG5
U266/LR7	NVn3cGFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nwS\|UxOCCwZz;tcC=>	MljJOFghcA>?	NYD6O3FoTE2VTx?=	Ml\YTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NXz4bFZEOTJ4M{G2NVk>
U266/dox4	M3TYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrUeJo1PTByIH7nM41t	NGjVXYs1QCCq	MUXEUXNQ	NXfrU5RVUW6qaXLpeJMh[2WubDDndo94fGh?	Mlr4NVI3OzF4MUm=
RPMI8226/LR5	NWnE[2l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFe4enc2ODBibnevcYw>	NIj5coI1QCCq	M4H0WmROW09?	NXK1VJFkUW6qaXLpeJMh[2WubDDndo94fGh?	MUexNlY{OTZzOR?=
H460	M{POSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rxe\|ExKM7:TR?=	MYO3NkBp	NGX5SXJFVVOR	NUDn[\|BpUUN3ME2xNFAhdk1?	NXrCbmg{OTJ4M{G2NlA>
H358	M4f2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3j3UlExKM7:TR?=	Moj0O\|IhcA>?	NF\1c25FVVOR	NEDYdVJKSzVyPUewJI5O	NH2yRlgyOjZ\|MU[yNC=>
H322	NWi5V41pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[xNEDPxE1?	NU\4bIhyPzJiaB?=	NFXPUmhFVVOR	MYrJR\|UxRTZ{MDDuUS=>	Mon3NVI3OzF4MkC=
H460	NEC2PVlHfW6ldHnvckBCe3OjeR?=	M4DTZ\|ExOCCwTR?=	NXLNbGhKOjRiaB?=	M3HLSGROW09?	NUHoZXlXUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?=	NFrYc2cyOjZ\|MU[yNC=>
LNCap-Pro5	M3TEdmZ2dmO2aX;uJGF{e2G7	MUexJO69VQ>?	M{DEPVQhcA>?	MlvzSG1UVw>?	NHHt[2NUfGGkaXzpfoV{KHB3Mx?=	MYWxOFYyOjV\|Mh?=
T29	NXjh[olxSXCxcITvd4l{KEG\|c3H5	MYq1NEBvVQ>?	NHTwbJM1QCCqIB?=	MY\EUXNQ	Ml\vTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NYX2U2MxOTZ5N{ixO\|k>
T29Kt1	M3j1V2Fxd3C2b4Ppd{BCe3OjeR?=	NV65S5pjPTBibl2=	M{PEVVQ5KGhi	NXyzeGxFTE2VTx?=	NUT2cG91UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MlKyNVY4PzhzN{m=
HCT116	M{LFVWFxd3C2b4Ppd{BCe3OjeR?=	NE\hR\|k2OCCwTR?=	M13GRlQ5KGhi	MX;EUXNQ	NYjmOVV7UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NWDoPGV5OTZ5N{ixO\|k>
HKe-3	Mnz2RZBweHSxc3nzJGF{e2G7	NF\XRoE2OCCwTR?=	NHTGe4Q1QCCqIB?=	NEDieXJFVVOR	NVruVXU5UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MXGxOlc4QDF5OR?=
NB-1691	NH[x[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfONUDPxE1?	NE\WeGo4OiCq		MWDJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV?	M4TDOFE4Pjh7Nki0
CHLA-255	NX7sdG43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HMOlEh\|ryP	MVq3NkBp		MlrMTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDJn	NH3ablkyPzZ6OU[4OC=>
SK-N-AS	NIPvS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXr2[IdSOSEQvF2=	NHr4OFU4OiCq		NXTEb29oUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=>	M1fQeFE4Pjh7Nki0
NB-1691	M1;oT2Z2dmO2aX;uJGF{e2G7	M33VflExKG6P	NGfqfnUzPCCq		MnjDV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=>	NGT3UlYyPzZ6OU[4OC=>
CHLA-255	NVjicVhLTnWwY4Tpc44hSXO\|YYm=	NVy4Xm9mOTBibl2=	NXHNem5YOjRiaB?=		NWXaN4RWVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS\|EheGijc3W=	Mn;pNVc3QDl4OES=
RPMI 8226	NUfpZ2ZHTnWwY4Tpc44hSXO\|YYm=	M4[4PFIxKG6P	MWq4JIg>		M1XuUHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NHu5TG8yQTR\|NkC1NC=>
MM.1S	NWH0NmZNTnWwY4Tpc44hSXO\|YYm=	M4\KWFIxKG6P	NYH5N3VoQCCq		M4S1enNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NVLJNFEyOTl2M{[wOVA>
U266	MYnGeY5kfGmxbjDBd5NigQ>?	NHPv[FUzOCCwTR?=	NXu0eXRDQCCq		Mm\aV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk>	MorLNVk1OzZyNUC=
OPM1	M1jx[mZ2dmO2aX;uJGF{e2G7	M3TMUlIxKG6P	NH7oTnM5KGh?		MXvTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>	MkjWNVk1OzZyNUC=
INA6	NFWz[llHfW6ldHnvckBCe3OjeR?=	NVX5eJQ2OjBibl2=	NIfJT3Q5KGh?		MYDTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>	Mk\yNVk1OzZyNUC=
OPM2	MUXGeY5kfGmxbjDBd5NigQ>?	MkHENlAhdk1?	M{TZUFghcA>?		Mm\3V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk>	MXqxPVQ{PjB3MB?=
RPMI 8226	M4nVRmZ2dmO2aX;uJGF{e2G7	MnfZNlAhdk1?	MXi4JIg>		Mm\wTY5lfWOnczDEUmEhe3mwdHjld4l{	NHrGTVIyQTR\|NkC1NC=>
BaF/3	NWewTGE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXTNVAxKG6P	M{nLdVQ5KGh?		MofQTWM2OD14LkKgcm0>	NIXXOIUzODNyNU[5Ni=>
BaF/3-p210	NGG1WVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUT0SHhPOTByIH7N	NUjBb2tjPDhiaB?=		NXSw[5NjUUN3ME20Mlchdk1?	M17aPFIxOzB3Nkmy
TCC-S	NI\4SG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3j4O\|ExOCCwTR?=	MonkOFghcA>?		NUPmdY9qUUN3ME2yMlghdk1?	MlnRNlA{ODV4OUK=
BaF/3	MnXpSpVv[3Srb36gRZN{[Xl?	MoOwOkBvVQ>?	NIDnVmc1QCCq		MnXTTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0	MUOyNFMxPTZ7Mh?=
BaF/3-p210	M3nJfWZ2dmO2aX;uJGF{e2G7	NF;CUmw3KG6P	NHvWR4Q1QCCq		MmPTTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=>	Ml;MNlA{ODV4OUK=
BaF/3-p210	NViwdXlnTnWwY4Tpc44hSXO\|YYm=	NXvmb2dKPiCwTR?=	MnvmNlQhcA>?		MkC4VoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ?	MmjDNlA{ODV4OUK=
Raji	MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXsNUDPxE1?	MnTiNlQhcA>?		NVi0dZIzWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NEnlcXYzOTF5MEm4PC=>
LCL-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYSxJO69VQ>?	NHLNNJczPCCq		NFfLZW1T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	NGTBPZgzOTF5MEm4PC=>
LCL-2	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPDOZUyKM7:TR?=	NFXNSW8zPCCq		NGXqWFRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	NH3jSFAzOTF5MEm4PC=>
BJAB	MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYC2cHRwOSEQvF2=	NVPTdZhxOjRiaB?=		M4T2XnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	MXGyNVE4ODl6OB?=
SNT-13	MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HLU\|Eh\|ryP	MYqyOEBp		M3XW[HJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	NXfrTXlHOjFzN{C5PFg>
SNT-16	M{DaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\TUYdPOSEQvF2=	NH7zNIYzPCCq		NUe4NWY5WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	MlPCNlEyPzB7OEi=
Jurkat	NU\OZnR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvRRph4OSEQvF2=	NHjVd4gzPCCq		NGXMcpNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	MVmyNVE4ODl6OB?=
KAI-3	NYHCZ2d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWH4bmVDOSEQvF2=	M4fkZ\|I1KGh?		NG\UTmxT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	NF7NNFEzOTF5MEm4PC=>
SNK-6	NH;0SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkToNUDPxE1?	MUmyOEBp		M3:2[nJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	MnnwNlEyPzB7OEi=
KHYG-1	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\QNUDPxE1?	Ml\2NlQhcA>?		M1zkc3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	Ml\SNlEyPzB7OEi=
SNT-16	NHHqblRCeG:ydH;zbZMhSXO\|YYm=	NXe2WYFvOSEQvF2=	NX3lc4pHPiCq		MomwTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NFnaRlAzOTF5MEm4PC=>
Jurkat	M4jDUGFxd3C2b4Ppd{BCe3OjeR?=	Mlz0NUDPxE1?	NIf3NoE3KGh?		M4\mVWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MXSyNVE4ODl6OB?=
KAI-3	M3HjdmFxd3C2b4Ppd{BCe3OjeR?=	M1jhUlEh\|ryP	NEPZSHk3KGh?		NIrKSFhKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MYOyNVE4ODl6OB?=
KHYG-1	M4PhW2Fxd3C2b4Ppd{BCe3OjeR?=	M1jxPVEh\|ryP	MlLOOkBp		NV;FSHFDUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	Mn7ONlEyPzB7OEi=
SNT-13	MmnYRY51cX[rcnHsJGF{e2G7	Ml35NUDPxE1?	MXKyOEBp		MXXJcoR2[2W\|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>	NEWxeZgzOTF5MEm4PC=>
SNT-16	NFTLUHBCdnSrdnnyZYwhSXO\|YYm=	M1rwblEh\|ryP	MWmyOEBp		NH3OdlBKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?	MUKyNVE4ODl6OB?=
KAI-3	MkjCRY51cX[rcnHsJGF{e2G7	MXexJO69VQ>?	NGm0dYozPCCq		M{H4Umlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>?	NX70UHN7OjFzN{C5PFg>
SNK-6	MX\BcpRqfmm{YXygRZN{[Xl?	NF3iR3kyKM7:TR?=	NYHtbm1HOjRiaB?=		MoWzTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX	NYXxNpNpOjFzN{C5PFg>
RAW 264.7	NVi2Z2llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUmxNFAhdk1?	NFT6UZU1QCCq		MUHS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	NYT0VFE1OjJ2MkexOVQ>
A375	M{D1OmFxd3C2b4Ppd{BCe3OjeR?=	NIqwNoQyOCCwTR?=	MlLhNlQhcA>?		M4XyO2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M1n1WlI{ODd7MEiz
BLM	NV3hZ\|RLSXCxcITvd4l{KEG\|c3H5	NYfLZVFiOTBibl2=	NFPzTWMzPCCq		M2jjV2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MV:yN\|A4QTB6Mx?=
A375	NVTRSlI2SXW2b4DoZYd6KEG\|c3H5	NEDYWmEyOCCwTR?=	NYHqbGlUOTJiaB?=		MXrJcoR2[2W\|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?=	Ml\FNlMxPzlyOEO=
BLM	NYnVelVmSXW2b4DoZYd6KEG\|c3H5	NYjaXJRrOTBibl2=	M{m0cFEzKGh?		MnnoTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=	NHvNZWUzOzB5OUC4Ny=>
H1299	NVv5Um5ZSXCxcITvd4l{KEG\|c3H5	NWrGUXNyQDBibl2=	MkPqNlQhcA>?	M2TudmROW09?	NYHsVZk4W2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:\|aYO=	NGjyNnkzPTN{M{[5Ny=>
Hut-78	NUHY[nVDTnWwY4Tpc44hSXO\|YYm=	NHX5dmEyODBibl2=	MkDUNlQhcA>?	NVrKTndiTE2VTx?=	M37zfmRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?=	NEfTXpczPTZ6MUOzOS=>
H9	M4ja[2Z2dmO2aX;uJGF{e2G7	M{PJeFExOCCwTR?=	MXiyOEBp	NFzXWI5FVVOR	M1H0emRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?=	MViyOVY5OTN\|NR?=
HH	MXnGeY5kfGmxbjDBd5NigQ>?	M4qzelExOCCwTR?=	Mki4NlQhcA>?	MoLESG1UVw>?	MV\kc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25?	MUiyOVY5OTN\|NR?=
Hut-78	MmG5UYloemG2aX;uJGF{e2G7	NH\6fZgyODBibl2=	M3i5PFI1KGh?	Mln2SG1UVw>?	Mnq2VoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?=	MV6yOVY5OTN\|NR?=
HH	NGqyXpBOcWe{YYTpc44hSXO\|YYm=	NH7qT5oyODBibl2=	MXeyOEBp	NU\CSnlWTE2VTx?=	M3zx[HJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW=	NHPQbFczPTZ6MUOzOS=>
U937	NYjqU5ZSTnWwY4Tpc44hSXO\|YYm=	NXKxXm96OTByIH7N	MV62JIg>		NX[1ZplmUW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?=	M{jNN\|I2PzlzNEe3
human PBMC	MWPGeY5kfGmxbjDBd5NigQ>?	NWD1VYJ3OTByIH7N	MV[yOEBp		MlXXTY5lfWOnczDJUE05KHKnbHXhd4U>	NF;nS3kzPTd7MUS3Oy=>
ES6	NYe5NmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjiNJZKSzVyPUCuNFAzOSCwTR?=	MmO3V2FPT0WU
SK-UT-1	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\qTGlEPTB;MD6xOlMhdk1?	NXjndoFpW0GQR1XS
SH-4	NV7tVGtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlz3TWM2OD1yLkG3N{BvVQ>?	NIf2SmxUSU6JRWK=
TE-9	M2e5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nEOmlEPTB;MD6xPFIhdk1?	MVPTRW5ITVJ?
A253	NWDDbHplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rwZWlEPTB;MD6yNFghdk1?	NX34UmlQW0GQR1XS
no-10	NX7Lb\|BkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIKzbFdKSzVyPUCuNlEhdk1?	MmnNV2FPT0WU
MMAC-SF	NXTtSHhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWK5WGV6UUN3ME2wMlIyPiCwTR?=	NGjuT4FUSU6JRWK=
A101D	NYHZOFl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWS4VY5wUUN3ME2wMlIzPSCwTR?=	NV[0SXAxW0GQR1XS
NTERA-S-cl-D1	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlP3TWM2OD1yLkK0N{BvVQ>?	M4qz[HNCVkeHUh?=
8-MG-BA	M3Tm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwMkWgcm0>	NGj1NGVUSU6JRWK=
KNS-42	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LQO2lEPTB;MD6yOVghdk1?	NHTBNZRUSU6JRWK=
LXF-289	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHVW5dKSzVyPUCuNlY6KG6P	NHL3ZoRUSU6JRWK=
OVCAR-4	Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfqVnlKSzVyPUCuNlg6KG6P	Mo\tV2FPT0WU
LOUCY	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLheVhzUUN3ME2wMlI6OyCwTR?=	NVPGd4RHW0GQR1XS
BB65-RCC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX75S2V7UUN3ME2wMlMxPCCwTR?=	NIjybYxUSU6JRWK=
D-542MG	NVXXTW8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW[xSpoxUUN3ME2wMlMzQSCwTR?=	MWLTRW5ITVJ?
ONS-76	NEf2OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zabWlEPTB;MD6zN{BvVQ>?	MXHTRW5ITVJ?
BB30-HNC	M1\ZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXO5e3J7UUN3ME2wMlM{PSCwTR?=	M1fSZ3NCVkeHUh?=
KS-1	NX;nWplQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTBwM{Sgcm0>	NWX2PYVpW0GQR1XS
A388	M4fJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjyTWM2OD1yLkO1OkBvVQ>?	NWnHTmY5W0GQR1XS
ES8	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrsSoxKSzVyPUCuOEBvVQ>?	MmTRV2FPT0WU
MZ2-MEL	M3nFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofKTWM2OD1yLkSwO{BvVQ>?	MUXTRW5ITVJ?
HCC2998	NE\IcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIK5fVVKSzVyPUCuOFEzKG6P	NUXXO\|FRW0GQR1XS
D-247MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTBwNEGzJI5O	MXHTRW5ITVJ?
ACN	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTIN\|dZUUN3ME2wMlQyPyCwTR?=	MXjTRW5ITVJ?
LB2518-MEL	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPVTWM2OD1yLkSyOUBvVQ>?	Ml35V2FPT0WU
ES1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTBwNEOgcm0>	M3TSUnNCVkeHUh?=
HCE-T	NWfNWWlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTBwNEO5JI5O	M13TZ3NCVkeHUh?=
OS-RC-2	M1zSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDKTWM2OD1yLkS0JI5O	NU\O[5gyW0GQR1XS
MFH-ino	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLnTWM2OD1yLkS0N{BvVQ>?	MlrIV2FPT0WU
OCUB-M	NXfoVJh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoWwTWM2OD1yLkS0O{BvVQ>?	M4jTSnNCVkeHUh?=
CP66-MEL	M4C3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTBwNEezJI5O	NHn2blhUSU6JRWK=
LB771-HNC	NFLxfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYK2XXg4UUN3ME2wMlQ4PCCwTR?=	MYnTRW5ITVJ?
DSH1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYO4bmg3UUN3ME2wMlQ5KG6P	M3vOT3NCVkeHUh?=
HUTU-80	NXuxTWR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTBwNUOzJI5O	MmPFV2FPT0WU
CESS	NF7HTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3izdGlEPTB;MD61N\|ghdk1?	Mm[yV2FPT0WU
NCI-H747	M3TQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTBwNUO5JI5O	NUnH[oV6W0GQR1XS
HT-144	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknBTWM2OD1yLkW3OkBvVQ>?	M2DoWnNCVkeHUh?=
COLO-829	MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTBwNkG0JI5O	MWLTRW5ITVJ?
A4-Fuk	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PoZWlEPTB;MD62NlMhdk1?	NYPSfIw1W0GQR1XS
GI-ME-N	M1THOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHj3WnhKSzVyPUCuOlM1KG6P	M4nSdHNCVkeHUh?=
LB831-BLC	M3rlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HqT2lEPTB;MD62OFEhdk1?	NX7QOIhpW0GQR1XS
HOP-62	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTBwNkS3JI5O	MoXuV2FPT0WU
BB49-HNC	MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTBwNkWyJI5O	MUXTRW5ITVJ?
D-336MG	MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHOcodIUUN3ME2wMlY2PyCwTR?=	M2TLTXNCVkeHUh?=
TK10	MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwNke5JI5O	Mmj4V2FPT0WU
Ramos-2G6-4C10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXv1RlhyUUN3ME2wMlY6OyCwTR?=	NV;Pd3JHW0GQR1XS
LB373-MEL-D	M13I[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrnfIRKSzVyPUCuO{BvVQ>?	M175PXNCVkeHUh?=
SF126	NILtNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnJZlFKSzVyPUCuO\|AyKG6P	NIeySmdUSU6JRWK=
UACC-257	NHTpdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTBwN{Ggcm0>	MW\TRW5ITVJ?
KINGS-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITVTpZKSzVyPUCuO\|IzKG6P	MU\TRW5ITVJ?
LS-513	M3;Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfONYVIUUN3ME2wMlc{QSCwTR?=	NHmyO4NUSU6JRWK=
GI-1	NHq5d3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PwTGlEPTB;MD63OlQhdk1?	MW\TRW5ITVJ?
ES7	NYHBNpB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jwdGlEPTB;MD63OlYhdk1?	M3XBTXNCVkeHUh?=
LB2241-RCC	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHvTWM2OD1yLkiwOEBvVQ>?	NVzRN4ZxW0GQR1XS
D-263MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f6cmlEPTB;MD64NFchdk1?	Mlm0V2FPT0WU
SW684	NIDOSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXJTW1iUUN3ME2wMlgzOSCwTR?=	MkGzV2FPT0WU
ML-2	NFvMTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTBwOEKxJI5O	MlWyV2FPT0WU
SK-LMS-1	MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVn0cYI3UUN3ME2wMlg2PCCwTR?=	NFHYWYVUSU6JRWK=
TE-5	NWPqTGlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjZdlZKSzVyPUCuPFY2KG6P	NWHhbFl4W0GQR1XS
QIMR-WIL	NYrFeY53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TOO2lEPTB;MD64PFkhdk1?	NY\lTZBxW0GQR1XS
NCI-H1355	NHXuW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTBwOEm1JI5O	MWTTRW5ITVJ?
SNB75	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TDfWlEPTB;MD65NVIhdk1?	M4jyc3NCVkeHUh?=
RXF393	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XtTGlEPTB;MD65NVQhdk1?	MmnJV2FPT0WU
IST-MEL1	M1v6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTlTWM2OD1yLkmxO{BvVQ>?	MnTFV2FPT0WU
SF268	M3\TbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[0VGNKSzVyPUCuPVI{KG6P	MlnvV2FPT0WU
KALS-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn3fGdKSzVyPUCuPVI2KG6P	MWfTRW5ITVJ?
HC-1	NEfGeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXixWVl4UUN3ME2wMlk4PSCwTR?=	NEKyWoxUSU6JRWK=
SW872	M1Tmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrs[FlIUUN3ME2wMlk6PiCwTR?=	NGLESHdUSU6JRWK=
PSN1	NIHUbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofMTWM2OD1zLkCxJI5O	MU\TRW5ITVJ?
TE-1	M3HtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTFwMEOgcm0>	M{K1dnNCVkeHUh?=
TE-10	NYLLXJVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nqPGlEPTB;MT6wN{BvVQ>?	M1j2[3NCVkeHUh?=
RKO	NG\SPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;jPGlEPTB;MT6wOkBvVQ>?	M{HlfHNCVkeHUh?=
LC-2-ad	NYC3[XE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;QW\|BKSzVyPUGuNFghdk1?	MWfTRW5ITVJ?
SK-MM-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTFwMEmgcm0>	MoC2V2FPT0WU
VA-ES-BJ	M3Ltfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TabmlEPTB;MT6wPUBvVQ>?	NX\aSplVW0GQR1XS
MZ7-mel	NWS2bpljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4W5fmlEPTB;MT6wPUBvVQ>?	NGGx[ItUSU6JRWK=
D-392MG	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPhTWM2OD1zLkGgcm0>	NUfmZYk1W0GQR1XS
CCRF-CEM	NXq1XJp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTFwMUOgcm0>	NI\x[3dUSU6JRWK=
EM-2	NFPiOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkK2TWM2OD1zLkG2JI5O	NHjQ[oFUSU6JRWK=
HAL-01	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTFwMUigcm0>	Mom1V2FPT0WU
TE-8	NFXZcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTFwMUmgcm0>	NFeyPXRUSU6JRWK=
NCI-H1882	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\lNZd4UUN3ME2xMlIhdk1?	MUjTRW5ITVJ?
Daudi	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYT4fpRoUUN3ME2xMlIzKG6P	MnPwV2FPT0WU
BL-41	M2OxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPib4VKSzVyPUGuNlUhdk1?	M3;V[nNCVkeHUh?=
SR	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrV[YVkUUN3ME2xMlI2KG6P	NF;hW3pUSU6JRWK=
KM12	M33xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\peJNKSzVyPUGuNlchdk1?	M3XCZXNCVkeHUh?=
K5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkm5TWM2OD1zLkK4JI5O	MXTTRW5ITVJ?
A3-KAW	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojDTWM2OD1zLkK4JI5O	MXLTRW5ITVJ?
CMK	NX62Z456T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfJTWM2OD1zLkK5JI5O	MmfPV2FPT0WU
Calu-6	M1Oy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVy4V2pjUUN3ME2xMlI6KG6P	NYfkOnc3W0GQR1XS
IST-SL2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K3fWlEPTB;MT6zNUBvVQ>?	NX;tZnljW0GQR1XS
OPM-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33McWlEPTB;MT6zN{BvVQ>?	MnjJV2FPT0WU
DU-4475	M1PMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;VNnhMUUN3ME2xMlM3KG6P	MoPPV2FPT0WU
ECC12	MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nLWWlEPTB;MT6zO{BvVQ>?	NVPOdZJzW0GQR1XS
L-540	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXP4emk5UUN3ME2xMlM4KG6P	M1rEcXNCVkeHUh?=
CAS-1	NVnjOG5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TiTmlEPTB;MT6zO{BvVQ>?	MkWzV2FPT0WU
PF-382	M{j3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTFwNEegcm0>	NGf5PIhUSU6JRWK=
LS-411N	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoX6TWM2OD1zLkWzJI5O	MkjBV2FPT0WU
NCI-H69	M2rCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTFwNUSgcm0>	NYHSbYZ{W0GQR1XS
NB12	MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTFwNU[gcm0>	Ml:1V2FPT0WU
HEL	M{O4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mne0TWM2OD1zLk[xJI5O	NI\lXIdUSU6JRWK=
GCIY	NWK1TJdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWW1dZE2UUN3ME2xMlYzKG6P	MoW2V2FPT0WU
EHEB	NHvnWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3H1TGlEPTB;MT62O{BvVQ>?	M4HoenNCVkeHUh?=
TGBC1TKB	M3HzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXzToF[UUN3ME2xMlcyKG6P	MUHTRW5ITVJ?
KURAMOCHI	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUCzTYlTUUN3ME2xMlczKG6P	MUHTRW5ITVJ?
U-266	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\je4prUUN3ME2xMlc3KG6P	NWLKWmREW0GQR1XS
LC4-1	NXfnNHZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TJOGlEPTB;MT63PUBvVQ>?	MVjTRW5ITVJ?
NCI-H2126	NW\oW3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGi2PYFKSzVyPUGuPEBvVQ>?	NVjudJhmW0GQR1XS
NCI-H1092	M{DYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\DPGlEPTB;MT64JI5O	NITMR4xUSU6JRWK=
GB-1	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\ITWM2OD1zLkixJI5O	NH3sco5USU6JRWK=
MV-4-11	NYK4cWZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTFwOEKgcm0>	NV;vPZhNW0GQR1XS
Becker	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLSTWM2OD1zLkizJI5O	MV;TRW5ITVJ?
MPP-89	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYW5XXBIUUN3ME2xMlg6KG6P	MortV2FPT0WU
BE-13	M37xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrGTWM2OD1zLkmzJI5O	MkjNV2FPT0WU
697	NFj4TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTFwOUmgcm0>	MmHQV2FPT0WU
NKM-1	MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJibl2=	M{LaSHNCVkeHUh?=
NB13	M{PLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGG2cJdKSzVyPUKgcm0>	Mo[yV2FPT0WU
LS-123	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrNTW9KSzVyPUKuNFIhdk1?	NXzPU2xTW0GQR1XS
NB17	NVTrUm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGCzTlhKSzVyPUKuNFQhdk1?	M1;jcHNCVkeHUh?=
LAN-6	NXHuNYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G1bGlEPTB;Mj6wOUBvVQ>?	NHy4V3ZUSU6JRWK=
EW-24	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PtNGlEPTB;Mj6wPEBvVQ>?	M1zyc3NCVkeHUh?=
NOS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTJwMUGgcm0>	MYfTRW5ITVJ?
BL-70	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XFNWlEPTB;Mj6xNkBvVQ>?	MYnTRW5ITVJ?
GT3TKB	M4G3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zQZ2lEPTB;Mj6xNkBvVQ>?	M1XtWnNCVkeHUh?=
HH	NITieYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\GVpRKSzVyPUKuNVMhdk1?	MXvTRW5ITVJ?
KE-37	MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3McJV1UUN3ME2yMlE{KG6P	NHns[ZNUSU6JRWK=
MOLT-4	NF;uOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TLcmlEPTB;Mj6xN{BvVQ>?	M2iycnNCVkeHUh?=
EKVX	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJwMUSgcm0>	MYjTRW5ITVJ?
KGN	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXmb4ltUUN3ME2yMlE2KG6P	NFzlSXJUSU6JRWK=
ES4	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1:0PWlEPTB;Mj6xOkBvVQ>?	NX;5cldPW0GQR1XS
SJSA-1	NF\qZ\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTJwMkGgcm0>	MonEV2FPT0WU
KMOE-2	NIOxXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\i[ZdKSzVyPUKuNlMhdk1?	MnTaV2FPT0WU
NB5	NYfBS2U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4q2VWlEPTB;Mj6yO{BvVQ>?	M2Di[nNCVkeHUh?=
BC-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIO5UIJKSzVyPUKuN\|Ehdk1?	MX7TRW5ITVJ?
NB10	M1LmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjZS4RiUUN3ME2yMlMzKG6P	M3TQc3NCVkeHUh?=
RPMI-8226	NVfJb4NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJwM{Wgcm0>	NEPrPGdUSU6JRWK=
SCC-3	M4f3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPYfFRKSzVyPUKuN\|chdk1?	M2\rNnNCVkeHUh?=
ARH-77	M1fTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTiXlVKSzVyPUKuN\|ghdk1?	MoXUV2FPT0WU
NCI-H748	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLJSZFKSzVyPUKuN\|khdk1?	MXvTRW5ITVJ?
KU812	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFi3UGVKSzVyPUKuOFIhdk1?	MoXBV2FPT0WU
NCI-H64	M2WyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rCVGlEPTB;Mj60OEBvVQ>?	M4jJeHNCVkeHUh?=
NB69	NI\4T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfUbGVnUUN3ME2yMlQ3KG6P	MXPTRW5ITVJ?
KNS-81-FD	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTJwNEigcm0>	NFTiPVhUSU6JRWK=
LB1047-RCC	Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TadWlEPTB;Mj61O{BvVQ>?	MnXJV2FPT0WU
EB-3	NHLJPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTJwNk[gcm0>	MYHTRW5ITVJ?
Mo-T	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLsXHpSUUN3ME2yMlc1KG6P	NVzQeopuW0GQR1XS
EW-16	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\4TWM2OD1{Lke1JI5O	NYnJU4ZxW0GQR1XS
CTV-1	MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLzTWM2OD1{Lkigcm0>	NYq3ToR6W0GQR1XS
ETK-1	M2HJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P1WGlEPTB;Mj64OEBvVQ>?	M1\pSnNCVkeHUh?=
C2BBe1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4D2TGlEPTB;Mj64PUBvVQ>?	MV7TRW5ITVJ?
MOLT-16	M2DS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\KV5ZKSzVyPUKuPFkhdk1?	NGTzbIlUSU6JRWK=
SW954	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2C1WGlEPTB;Mj65JI5O	NH\6d\|JUSU6JRWK=
HT	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV:4N2dIUUN3ME2zMlAzKG6P	NXTRdodXW0GQR1XS
KARPAS-299	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4noV2lEPTB;Mz6wOkBvVQ>?	NVjYTpBGW0GQR1XS
MONO-MAC-6	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIT4WHNKSzVyPUOuNUBvVQ>?	NHywWGJUSU6JRWK=
CGTH-W-1	MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;lWmxKSzVyPUOuNUBvVQ>?	NVH1[\|VrW0GQR1XS
SK-PN-DW	NULrb2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnWe3Y2UUN3ME2zMlE1KG6P	MYjTRW5ITVJ?
CW-2	M{S0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPTTWM2OD1\|LkKxJI5O	NET2NpdUSU6JRWK=
SK-N-DZ	NYS0fYRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrzfotNUUN3ME2zMlI3KG6P	M1j6RnNCVkeHUh?=
NEC8	NXzLPVJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTNwM{Wgcm0>	NW[5VXViW0GQR1XS
LB996-RCC	NHv5Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\4SFdKSzVyPUOuOEBvVQ>?	NHfwVVZUSU6JRWK=
DB	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzrPWlDUUN3ME2zMlQyKG6P	M2nQ[HNCVkeHUh?=
TE-15	NVnuNXFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTGTWM2OD1\|LkSzJI5O	M1WxfnNCVkeHUh?=
COR-L88	NE\4cGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjrcoVKSzVyPUOuOFchdk1?	MkH0V2FPT0WU
LAMA-84	NFvLZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2L4R2lEPTB;Mz60PUBvVQ>?	Mo\1V2FPT0WU
MEG-01	NUjQc\|ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmX2TWM2OD1\|LkS5JI5O	MYjTRW5ITVJ?
LOXIMVI	NILqVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHGUmVKSzVyPUOuOUBvVQ>?	NF;OPIJUSU6JRWK=
RPMI-8402	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;WXlluUUN3ME2zMlUhdk1?	M1z0VHNCVkeHUh?=
KARPAS-45	NHjXUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nEemlEPTB;Mz61OEBvVQ>?	MVPTRW5ITVJ?
HCC1187	NIS0VZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1ftXGlEPTB;Mz61OEBvVQ>?	NYPUT5RHW0GQR1XS
MZ1-PC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUOzTYdTUUN3ME2zMlU1KG6P	M2nJ[HNCVkeHUh?=
no-11	M{jPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTBTWM2OD1\|LkW1JI5O	MlrxV2FPT0WU
EVSA-T	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;ndIpKSzVyPUOuOkBvVQ>?	MknjV2FPT0WU
DJM-1	NULrTXRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnwSGZKSzVyPUOuOlMhdk1?	MVfTRW5ITVJ?
COLO-684	NIDrTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTNwNk[gcm0>	NFvjVIpUSU6JRWK=
NMC-G1	Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;KR5JKSzVyPUOuOlghdk1?	M4r3S3NCVkeHUh?=
LC-1F	NYfKV25TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PQbWlEPTB;Mz63OEBvVQ>?	M2TYe3NCVkeHUh?=
RL95-2	NUHQdJJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne3TWM2OD1\|Lke5JI5O	M2rJ[XNCVkeHUh?=
COLO-320-HSR	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELCbm9KSzVyPUOuPVIhdk1?	M3PQfnNCVkeHUh?=
RCC10RGB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3W4U2lEPTB;Mz65N{BvVQ>?	Mmn3V2FPT0WU
HD-MY-Z	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTNwOUOgcm0>	MlPHV2FPT0WU
NCI-H2141	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPkO2NGUUN3ME20MlA2KG6P	NWrTenp5W0GQR1XS
K-562	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHSUXpKSzVyPUSuNVIhdk1?	MmnnV2FPT0WU
NCI-H1648	M1G0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;FbYw1UUN3ME20MlE{KG6P	NHG0OpBUSU6JRWK=
OMC-1	M2jVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETid5pKSzVyPUSuNVghdk1?	MWPTRW5ITVJ?
LB647-SCLC	NXLaVoFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVq0SpRqUUN3ME20MlIzKG6P	Mn\HV2FPT0WU
TE-12	NFj4NGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTRwMkWgcm0>	NVu5PXhzW0GQR1XS
NOMO-1	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1f5VGlEPTB;ND6zN{BvVQ>?	NXnlPHRDW0GQR1XS
Raji	NFfhPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfwWoxDUUN3ME20MlQ3KG6P	NGCxfI1USU6JRWK=
NALM-6	M3ftVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1S3XWlEPTB;ND60PUBvVQ>?	Moe4V2FPT0WU
HL-60	NHnuWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfnOVBuUUN3ME20MlY4KG6P	MVTTRW5ITVJ?
IST-SL1	NX3OO2dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzOT2pKSzVyPUSuOlghdk1?	M2W0[HNCVkeHUh?=
MHH-PREB-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTRwOE[gcm0>	MWHTRW5ITVJ?
MHH-NB-11	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXrTWRDUUN3ME20MlkyKG6P	MonkV2FPT0WU
JiyoyeP-2003	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFW5XGhKSzVyPUWgcm0>	M1\Q[XNCVkeHUh?=
SBC-1	NWjDNXJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jMUWlEPTB;NT6wNUBvVQ>?	NFvzRoxUSU6JRWK=
CHP-126	NFfPbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULnXo5tUUN3ME21MlA3KG6P	NVPvVFhqW0GQR1XS
LU-139	NHPONVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrvTWM2OD13LkGzJI5O	NYrybmZbW0GQR1XS
NCI-SNU-5	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDrdpdKSzVyPUWuNVchdk1?	NXnqRXl4W0GQR1XS
SW962	NUfnOYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\oS\|hKSzVyPUWuNlEhdk1?	MWHTRW5ITVJ?
EW-1	NETLbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTVwM{Ggcm0>	M3\Zc3NCVkeHUh?=
NCI-H1417	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LBN2lEPTB;NT61NUBvVQ>?	Ml7xV2FPT0WU
LU-65	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkP3TWM2OD13Lki0JI5O	MWPTRW5ITVJ?
D-502MG	NYHrN3lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnCOVN7UUN3ME22MlM4KG6P	M3XvRnNCVkeHUh?=
BC-3	NEH6cm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjZdVNKSzVyPU[uOlEhdk1?	Mlj4V2FPT0WU
GDM-1	M4GzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7ITWM2OD14Lke3JI5O	M{\pZnNCVkeHUh?=
NCI-H2196	M2HDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTZwODDuUS=>	NHXDWFVUSU6JRWK=
NB1	NGHWbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLxcG1PUUN3ME22Mlg5KG6P	MYXTRW5ITVJ?
NCI-H345	NGHDeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoqxTWM2OD15LkKgcm0>	MXzTRW5ITVJ?
SU-DHL-1	NWXZdHdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;3PGlEPTB;Nz6yOEBvVQ>?	NX\reYpZW0GQR1XS
JVM-2	NGLodmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzCTWM2OD15LkK4JI5O	MoH0V2FPT0WU
LU-134-A	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrvdW9KSzVyPUeuN\|khdk1?	MYXTRW5ITVJ?
NCI-H1694	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoSzTWM2OD15LkW4JI5O	NIXib3lUSU6JRWK=
NCI-SNU-16	M{LtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\DTWM2OD15Lk[1JI5O	MluzV2FPT0WU
L-363	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HyUmlEPTB;Nz63JI5O	NGm1UG9USU6JRWK=
KG-1	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTdwOUSgcm0>	NEXnXFNUSU6JRWK=
MN-60	NXjUeW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTaTWM2OD16LkG0JI5O	MX3TRW5ITVJ?
NB6	NF35VGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnVTGVKSzVyPUiuOFghdk1?	M4DVcXNCVkeHUh?=
MLMA	NIPlRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXKO3pKSzVyPUiuPFUhdk1?	MXzTRW5ITVJ?
ATN-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jYNGlEPTB;OD64PUBvVQ>?	MYHTRW5ITVJ?
SK-NEP-1	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjIXVZoUUN3ME25MlAyKG6P	NIHHcIhUSU6JRWK=
DMS-114	NV7i[pJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTlwNkKgcm0>	MoHjV2FPT0WU
CTB-1	M3;ZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfBc5ZMUUN3ME25MlY4KG6P	M4rT[HNCVkeHUh?=
NCI-H2081	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XMVmlEPTB;MUCuNFkhdk1?	MoHWV2FPT0WU
ES5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33LTmlEPTB;MUCuN\|ghdk1?	NXLqW4c3W0GQR1XS
HCC1599	M1Ttb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\3O\|FKSzVyPUGxMlkyKG6P	NEXyS2pUSU6JRWK=
NCI-H23	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXH0c4tIUUN3ME2xNk4yOiCwTR?=	NUfrXpg1W0GQR1XS
NCI-H1581	NWrRTFNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoH2TWM2OD1zMj6yPEBvVQ>?	M3i3OnNCVkeHUh?=
JVM-3	NU\EOWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnrW3lwUUN3ME2xNk46QSCwTR?=	NW[zem16W0GQR1XS
NCI-SNU-1	M2XYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{T1PGlEPTB;MUOuNVkhdk1?	NYm0eFNYW0GQR1XS
NB7	NYnFWWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\wPGlEPTB;MUWuPVIhdk1?	NIm3O4tUSU6JRWK=
JAR	Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7XNGdKSzVyPUG2MlE{KG6P	NIGzbWNUSU6JRWK=
TGW	M3;PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fudmlEPTB;MU[uOFghdk1?	MXXTRW5ITVJ?
U-87-MG	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HvRWlEPTB;MU[uO\|Yhdk1?	M{XjcnNCVkeHUh?=
NCI-H1436	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTF5LkCxJI5O	MVzTRW5ITVJ?
GOTO	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3OwSmlEPTB;MUeuNFYhdk1?	M3LVbHNCVkeHUh?=
COLO-800	NUDnOZRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTF5Lk[0JI5O	MV;TRW5ITVJ?
MFM-223	NYSzPJM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTF5LkmxJI5O	MnTZV2FPT0WU
EW-18	M1rucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1yzbmlEPTB;MUeuPVYhdk1?	M{XrWXNCVkeHUh?=
NB14	MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTF5Lkm4JI5O	MX7TRW5ITVJ?
EB2	NYCzd416T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Lie2lEPTB;MUiuNFghdk1?	NY\3SII1W0GQR1XS
EoL-1-	NUP6UI1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXlVZJCUUN3ME2xPE4{OSCwTR?=	MmLYV2FPT0WU
NCCIT	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfxdlBKSzVyPUG4MlM3KG6P	M2j1OHNCVkeHUh?=
DG-75	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTF6Lk[xJI5O	MXfTRW5ITVJ?
HCC2218	M1W5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTF7LkWgcm0>	MkOwV2FPT0WU
TE-6	NYLaZnJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEezR41KSzVyPUKwMlA5KG6P	NWftVHE{W0GQR1XS
SF539	M4OxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHGboZNUUN3ME2yNE43PyCwTR?=	M3L3fHNCVkeHUh?=
NCI-H446	NYTjW2o3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvyTWFuUUN3ME2yNU4yQCCwTR?=	M1fQU3NCVkeHUh?=
IST-MES1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJ{Lke3JI5O	Mn75V2FPT0WU
NCI-H82	M2f4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn2TWM2OD1{Mz6wNkBvVQ>?	NVHOe2VWW0GQR1XS
HCC2157	NEfLV\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTJ\|LkGzJI5O	M2XRPHNCVkeHUh?=
EW-12	MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTJ\|LkG3JI5O	MWjTRW5ITVJ?
SIMA	MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TscGlEPTB;MkOuN\|ghdk1?	M1XPWHNCVkeHUh?=
DOHH-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTJ\|LkS1JI5O	NV;I[GVQW0GQR1XS
IM-9	M3X3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTJ\|LkW0JI5O	NX21XGtYW0GQR1XS
EC-GI-10	M3LsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTJ2LkKzJI5O	Mn:1V2FPT0WU
HDLM-2	NHH5SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXu0[IFVUUN3ME2yOE42PCCwTR?=	NVr0bpZwW0GQR1XS
LS-1034	NX\KbVFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYm2V2Q3UUN3ME2yOU44PSCwTR?=	MYDTRW5ITVJ?
REH	M2W5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nBdGlEPTB;Mk[uOFEhdk1?	NGTOfo1USU6JRWK=
LU-165	M1;remdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fjUmlEPTB;Mk[uO\|Ihdk1?	MojFV2FPT0WU
NH-12	NWC1PWt{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PnXGlEPTB;MkeuOlchdk1?	NWjK[GtlW0GQR1XS
WSU-NHL	Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1OzcmlEPTB;MkiuN\|khdk1?	MlvVV2FPT0WU
ECC4	M{C4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HEdmlEPTB;MkiuO\|khdk1?	M2X3e3NCVkeHUh?=
OCI-AML2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTJ7Lk[5JI5O	MXXTRW5ITVJ?
EW-3	NH7xdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXHb5VKSzVyPUOwMlU6KG6P	MoLLV2FPT0WU
NCI-H526	NX3V[YlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\FS2lEPTB;M{KuOVQhdk1?	MorPV2FPT0WU
NCI-H719	M4niUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XWXmlEPTB;M{SuN\|Ehdk1?	NIP4OoJUSU6JRWK=
KARPAS-422	NUnqUZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1WzXmlEPTB;M{WuNFQhdk1?	NEPDV2xUSU6JRWK=
SK-MEL-1	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTN3LkG3JI5O	M3XzNnNCVkeHUh?=
ES3	MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nXV2lEPTB;M{WuNVkhdk1?	NEe0XoNUSU6JRWK=
UACC-812	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvSO2xKSzVyPUO1MlQ1KG6P	MnziV2FPT0WU
C8166	NIq1V4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTN3Lkegcm0>	MnH4V2FPT0WU
MDA-MB-134-VI	NELLd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{e5S2lEPTB;M{WuPFchdk1?	MXfTRW5ITVJ?
D-283MED	MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvMTWM2OD1\|Nz63PUBvVQ>?	MUTTRW5ITVJ?
SHP-77	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHXeVF1UUN3ME2zPE4xOyCwTR?=	MnziV2FPT0WU
NCI-H2227	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1exSWlEPTB;NECuOFkhdk1?	MV;TRW5ITVJ?
SKM-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnNTXRmUUN3ME20Nk43OyCwTR?=	MWPTRW5ITVJ?
L-428	M1TkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37UT2lEPTB;NEOuPFYhdk1?	NXjJZ3N{W0GQR1XS
RPMI-6666	NYDrcY9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHYTWM2OD12NT64PUBvVQ>?	M3vJfHNCVkeHUh?=
NCI-H716	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3MN3FKSzVyPUS4MlgyKG6P	NIjr[m9USU6JRWK=
DMS-79	M1izSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPqR2lKSzVyPUWwMlcyKG6P	NUn6NJprW0GQR1XS
RS4-11	NXLqOYNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jaV2lEPTB;NUCuPFghdk1?	NILkblZUSU6JRWK=
NCI-H720	M13ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFuxPHNKSzVyPUWxMlEyKG6P	MULTRW5ITVJ?
MC-CAR	M{fjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\aNFlKSzVyPUWxMlUzKG6P	MofZV2FPT0WU
TALL-1	M4[yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPBTWM2OD13Mz65NUBvVQ>?	NHfQWW9USU6JRWK=
NCI-N87	NGfQeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoSzTWM2OD13ND6xPEBvVQ>?	NVr0Wm9qW0GQR1XS
P30-OHK	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTV2Lk[xJI5O	MUPTRW5ITVJ?
LP-1	M2HK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITCfohKSzVyPU[xMlI5KG6P	M1;OZnNCVkeHUh?=
YT	NUnGepN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4SybGlEPTB;NkGuPEBvVQ>?	MnzNV2FPT0WU
MRK-nu-1	M13DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXKfZk4UUN3ME22NU45OiCwTR?=	M{CwSXNCVkeHUh?=
BT-474	MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTZ3IH7N	M3Pq[3NCVkeHUh?=
NCI-H322M	M3fYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTZ4LkGxJI5O	M{\BXnNCVkeHUh?=
NCI-H128	M4ixZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2KwfWlEPTB;N{SuO\|chdk1?	M3WyT3NCVkeHUh?=
KMS-12-PE	NYDvfJFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTd4LkK0JI5O	NH\pOXdUSU6JRWK=
KP-N-YS	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDrdopKSzVyPUe2Mlc1KG6P	NXL3SVVkW0GQR1XS
ALL-PO	M323SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknVTWM2OD15Nz62OkBvVQ>?	MWDTRW5ITVJ?
EW-13	M1PPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\PNXZKSzVyPUe3Mlc3KG6P	MlXrV2FPT0WU
EW-11	NIDiPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGKySVNKSzVyPUe4MlUzKG6P	NFLKV3RUSU6JRWK=
SK-N-FI	NGjvOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfHdoV7UUN3ME24NE4zKG6P	M32zTnNCVkeHUh?=
CAL-148	M4nNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;yTWM2OD16MT64OEBvVQ>?	NXnvSolPW0GQR1XS
RL	NGP5c4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm4TWM2OD16Nj6wPUBvVQ>?	NF3teZFUSU6JRWK=
AM-38	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLtSGxsUUN3ME24PE4xQCCwTR?=	MVrTRW5ITVJ?
RH-1	MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrobI4xUUN3ME25PU45PSCwTR?=	M4f5fnNCVkeHUh?=
NCI-H1770	M4DyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3hTWM2OD1zMEKuOFkhdk1?	Mm\DV2FPT0WU
SIG-M5	NGjDTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnWcmJNUUN3ME2xNFUvODZibl2=	NXzzN\|NSW0GQR1XS
GR-ST	NYiwOWZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV6xcJc{UUN3ME2xNVMvOzRibl2=	MYnTRW5ITVJ?
ST486	NHmwd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{m2cWlEPTB;MUG0MlA3KG6P	NIrje2pUSU6JRWK=
NCI-H1650	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDLXFhKSzVyPUGxOU4zQSCwTR?=	M4m5THNCVkeHUh?=
MHH-CALL-2	MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3pT2V1UUN3ME2xNVUvPyCwTR?=	MWfTRW5ITVJ?
BV-173	MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTF{Mj63NUBvVQ>?	NFTaUWpUSU6JRWK=
MC116	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTF2OD64OUBvVQ>?	Mof0V2FPT0WU
NCI-H524	M3zpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoiwTWM2OD1zNUmuNUBvVQ>?	NYXQV3JxW0GQR1XS
SCLC-21H	NYP5VYY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTF3OT60NUBvVQ>?	MmfJV2FPT0WU
NCI-H1304	M{m2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoGzTWM2OD1zNkmuNlEhdk1?	NIHLN2ZUSU6JRWK=
NCI-H510A	NG\SRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTF6NT6zO{BvVQ>?	M1\mN3NCVkeHUh?=
NCI-H209	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\kTWM2OD1zOU[uOVIhdk1?	MYjTRW5ITVJ?
KM-H2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTF7Nz6wOUBvVQ>?	M{jiVXNCVkeHUh?=
NCI-H1395	M{\mU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\FcGFjUUN3ME2yNVAvOTNibl2=	NWjmeHJvW0GQR1XS
NCI-H1155	M3L0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jIeWlEPTB;MkOwMlMzKG6P	MUPTRW5ITVJ?
COR-L279	NV;lN3hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvQVnRKSzVyPUK1Nk4yPyCwTR?=	NEfsOHVUSU6JRWK=
NCI-H1299	NWrWd4pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrQTWM2OD1{NkGuO\|Ehdk1?	M2fzV3NCVkeHUh?=
EW-22	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nncmlEPTB;Mk[zMlc2KG6P	MUTTRW5ITVJ?
SK-MEL-2	M1PHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLsVlRKSzVyPUK4NU46KG6P	NYficFcyW0GQR1XS
KASUMI-1	NXTaWmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTJ6Mz6wOUBvVQ>?	M{e4RXNCVkeHUh?=
NCI-H187	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTJ6Nz6wPEBvVQ>?	NVn1SWFzW0GQR1XS
NCI-H2171	NYfQNIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPwTWM2OD1{OEiuPVIhdk1?	MVLTRW5ITVJ?
LNCaP-Clone-FGC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILibVhKSzVyPUK5OU4zPiCwTR?=	NU\vWoN{W0GQR1XS
NCI-H1522	NI\0[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTNyNz6wOUBvVQ>?	MlHSV2FPT0WU
SCH	Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzIO5VXUUN3ME2zNlIvOjJibl2=	MmnZV2FPT0WU
THP-1	NYL0OJJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3Uc5BKSzVyPUOyNk43KG6P	MX;TRW5ITVJ?
SNU-C1	NHXpN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTzdJVKSzVyPUO2Nk4xQSCwTR?=	Ml:5V2FPT0WU
CA46	NUPMTIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnnNINKSzVyPUO3N{43OyCwTR?=	NIjIO4dUSU6JRWK=
NCI-H1963	NYTPclg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTN6Nj6xPUBvVQ>?	M4rKOXNCVkeHUh?=
DEL	NGnaR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITONYNKSzVyPUO5NU4zPyCwTR?=	NIrtO3JUSU6JRWK=
TUR	NELFZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7rPXZKSzVyPUO5Ok43OSCwTR?=	M1\lVHNCVkeHUh?=
NCI-H226	NFr6RlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLHZYZKSzVyPUSwN{4zOyCwTR?=	NH[4[2RUSU6JRWK=
COLO-668	M{K1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TJZmlEPTB;NECzMlU4KG6P	MljmV2FPT0WU
CPC-N	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXGenNKSzVyPUSwN{44PyCwTR?=	MnHZV2FPT0WU
NCI-H889	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfD[4xQUUN3ME20OlEvQTJibl2=	NVrG[XRlW0GQR1XS
J-RT3-T3-5	M2nVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIP0WG1KSzVyPUWzNk42PyCwTR?=	M3:5[nNCVkeHUh?=
MSTO-211H	MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDzfGlKSzVyPUW3OE4zPiCwTR?=	NE\SXJFUSU6JRWK=
SCC-15	NHy2PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPVXY1ZUUN3ME22OlcvPDdibl2=	MoDCV2FPT0WU
SUP-T1	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELsd21KSzVyPU[4Ok4xPCCwTR?=	NYfXbItZW0GQR1XS
DMS-153	NFnkZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HWTWlEPTB;N{S2Mlg{KG6P	M320fnNCVkeHUh?=
MS-1	NImwN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXWcFZKSzVyPUe1PU41OiCwTR?=	MYrTRW5ITVJ?
TC-YIK	NYnucWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTGOZVKSzVyPUe4NU4xOSCwTR?=	NXfjR\|ZoW0GQR1XS
RPMI-8866	M2jy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGmzSIVKSzVyPUGwNFYvOjhizszN	Mk[zV2FPT0WU
KY821	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHpTWM2OD1zMEO2MlA1KM7:TR?=	M4HHdnNCVkeHUh?=
P31-FUJ	Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzWTWM2OD1zMUGyMlc2KM7:TR?=	NVLIfphOW0GQR1XS
COLO-824	M2m5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojkTWM2OD1zMk[xMlc5KM7:TR?=	M37DTHNCVkeHUh?=
U-698-M	M3vhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnLPZB3UUN3ME2yNlYzNjF3IN88US=>	MnLOV2FPT0WU
TE-441-T	NF7JdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJ3MkGuO{DPxE1?	MWfTRW5ITVJ?
IMR-5	M4jVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTN2MEmuOlIh\|ryP	NY\kRoJjW0GQR1XS
NCI-H1838	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoL2TWM2OD12MUi2MlMzKM7:TR?=	NUPZXGpSW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-PERK / ATF-4; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. GRP-78 / GADD-34; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-12 / pro-caspase-3; PubMed: 15509775 Mol Cell Biol MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-9; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. p-IκBα / IκBα; PubMed: 20335171 J Biol Chem PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. COX-2 / cIAP2; PubMed: 24085292 J Biol Chem NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times. Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin.	15509775 20335171 24085292
Immunofluorescence	Vimentin; PubMed: 19010849 Clin Cancer Res ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). Ubiquitin; PubMed: 19010849 Clin Cancer Res IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective).	19010849
Growth inhibition assay	Cell viability ; PubMed: 20571067 Mol Cancer Ther A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). P < 0.01.	20571067
ELISA	IL-8; PubMed: 24085292 J Biol Chem NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.	24085292

In vivo

The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. ^[2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. ^[3]

Protocol

Kinase Assay: ^[4]	+ Expand Kinetic Methods: In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λ_ex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research: ^[5]	+ Expand Cell lines: Human multiple myeloma cells line U266 Concentrations: ~10 μM Incubation Time: 2 days Method: The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: Human plasmacytoma xenografts RPMI 8226 Formulation: Saline Dosages: 1 mg/kg Administration: i.v. twice weekly for 4 weeks, then once weekly (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	76 mg/mL (197.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Bortezomib (PS-341) SDF

Molecular Weight	384.24
Formula	C₁₉H₂₅BN₄O₄
CAS No.	179324-69-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	LDP-341, MLM341

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03993262	Not yet recruiting	Drug: Bortezomib\|Drug: Placebo	Autoimmune Encephalitis	Jena University Hospital	October 1 2019	Phase 2
NCT00425503	Completed	Drug: PS-341 (bortezomib)	Prostate Neoplasms	Baylor College of Medicine\|Millennium Pharmaceuticals Inc.	December 2001	Phase 2
NCT00025376	Completed	Drug: PS-341\|Procedure: Tumor Biopsy	Kidney Cancer	University of Chicago\|National Cancer Institute (NCI)	October 2001	Phase 2
NCT00237627	Completed	Drug: PS-341\|Drug: Doxil\|Drug: Velcade	Breast Cancer\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Ovarian Cancer\|Unspecified Adult Solid Tumor Protocol Specific	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	May 2001	Phase 1\|Phase 2
NCT00006773	Terminated	Drug: bortezomib	Adult Anaplastic Astrocytoma\|Adult Anaplastic Oligodendroglioma\|Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Recurrent Adult Brain Tumor	National Cancer Institute (NCI)	May 2001	Phase 1
NCT00373906	Completed	Drug: Bortezomib (Velcade)	MALT Lymphoma	Medical University of Vienna		Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
Answer:
S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Pan Proteasome Inhibitor

Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.
FDA-approved Proteasome Inhibitor

Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.
Newest Proteasome Inhibitor

Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products

VR23 ^New

VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.
Marimastat (BB-2516) ^New

Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
MG-132

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Carfilzomib (PR-171)

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.
Ixazomib (MLN2238)

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and K_i of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.
Ixazomib Citrate (MLN9708)

Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.
Celastrol

Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

Features:A potent antioxidant and anti-inflammatory drug.
Oprozomib (ONX 0912)

Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)

Cited by 279 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Bortezomib (PS-341) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)

Cited by 279 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Bortezomib (PS-341) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)